ProAir® Digihaler® (albuterol sulfate; Teva) Inhalation Powder is now available for patients aged ≥4 years for the treatment or prevention of bronchospasm with reversible obstructive airway disease, and for the prevention of exercise-induced bronchospasm (EIB).
This week we cover the discontinuation of a trial investigating a potential COVID-19 treatment; A safety alert for toxic hand sanitizers; Vaccine guidance in the time of the pandemic; And new treatments in HIV and myelodysplastic syndromes.
The COVPN is part of “Operation Warp Speed”, a partnership led by the Department of Health and Human Services (HHS) to accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics.
Highest rates of adverse events seen within first month after initiating short course of oral steroids.
A phase 3 trial evaluating sarilumab (Sanofi and Regeneron), an interleukin-6 antagonist, in patients with COVID-19 requiring mechanical ventilation did not meet its primary and key secondary end points.
Siltuximab is currently marketed under the trade name Sylvant and is indicated for the treatment of multicentric Castleman’s disease.
Researchers estimate an excess of U.S. deaths 28 percent higher than official COVID-19 death counts.
Consumers can protect themselves by checking FDA website for a list of approved antibody tests, testing companies
Fauci and other health officials also testified before US Senate about the need to build up confidence in vaccination.
8 percent of children need ICU admission; risk up with age <1 month, male sex, pre-existing conditions.
